In view of some studies showing that DNA damage may act as a potential target for therapeutic intervention [5, 17, 18], the present study explored whether ADAs modified the therapeutic effects of po-TACE treatment on HCC through a stratified analysis based on the different levels of ADAs in the tissues with HCC (Table 4). This evidence concerns the gene AGPS and hepatocellular carcinoma.